交易 Gilead 差价合约 — 实时图表

您好, user_no_name

立即交易

存入

退出
登录注册
ZH

语言

English English (Global)

English English (EU)

English English (UK)

English English (AU)

English English (ZA)

English English (St. Vincent)

Deutsch German

Español Spanish (Latam)

Español Spanish (Spain)

Français French

Dansk Danish

Italiano Italian

Nederlands Dutch

العربية Arabic

Svenka Swedish

Tiếng việt Vietnamese

Bahasa Melayu Malay

ภาษาไทย Thai

繁體中文 Traditional Chinese

简体中文 Simplified Chinese

Tagalog Tagalog

தமிழ் Tamil

हिन्दी Hindi

Português Portuguese

Bahasa Indonesia Indonesian

한국어 Korean

English English (BVI)
市场

产品

外汇

股票

商品

指数

加密貨幣CFD

ETFs

债券
交易

交易平台

Web 平台

应用

TradingView

MT4

MT5

Trading Central

交易工具

差价合约交易计算器

外汇交易保证金计算器

商品利润计算器

外汇交易利润计算器

经济事件日历

交易信息

差价合约交易

差价合约资产列表

交易条件

交易时段

到期日

近期交易休市日

每周到期展期

交易功能

市场深度
学习

学习交易

术语表

教育中心

交易基础知识

视频库

新闻与分析

新闻

社区
推广

marketsClub

欢迎奖金

积分奖

推荐促销
加盟

加盟

IB
关于

Markets.com 简介

为何选择 markets.com

全球服务

集团简介

奖项和媒体

帮助与支持

常见问题解答

帮助中心

联系客服

投诉

数据与安全

安全上网

Cookie 披露声明

法律资源包

合法交易条例

搜索

语言

登录注册

Gilead 实时图表

5m 15m 30m 1h 4h 1d 1w

金融票据基础知识

历史数据

日期	关闭	更改	更改(%)：	开盘价	高	低

Gilead news

Frances Wang 2024 Aug 04, 16:00

The Week Ahead: ISM services, SMCI

CFD Trading

Magnificent Seven earnings take centre stage in the markets this week

Neil Wilson 2024 Apr 19, 01:00

Week ahead: Wall Street’s Magnificent Seven earnings are up

Commodities Forex Indices Shares

Neil Wilson 2024 Feb 01, 08:03

Week ahead: Earnings season climax

Forex Indices

Neil Wilson 2023 Nov 03, 04:01

Week ahead: RBA poised to hike?

Forex Indices

Neil Wilson 2023 Apr 21, 05:00

Week ahead: Megacap tech and 1-in-3 Dow components set to report

信息

点差

0.70

点差(%)

0.6200 %

杠杆

1:10

隔夜利息（买入）

-0.0597 %

隔夜利息（卖出）

-0.0292 %

币种

USD

交易时间

市场关闭

星期五

13:31 - 19:59

星期一

13:31-19:59

星期二

13:31-19:59

星期三

13:31-19:59

星期四

13:31-19:59

分析和统计

开盘价

---

昨收

---

52 周高点/低点

--- – ---

市值

141260685312

在外流通股份

1243929984

财报日（下一）

2013-01-28

股息收益率

2025-06-27

除息日

2025-06-13

远期年度股息率

3.16

远期年股息率

0.0287

每股收益

4.76

详细了解此金融票据

Gilead Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.